Author's response to reviews

Title: Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells

Authors:

Akinori Sato (zenpaku@ndmc.ac.jp)
Takako Asano (urotaka5@ndmc.ac.jp)
Makoto Isono (drur589@ndmc.ac.jp)
Keiichi Ito (itok@ndmc.ac.jp)
Tomohiko Asano (otosan@ndmc.ac.jp)

Version: 6
Date: 10 August 2014

Author's response to reviews: see over
August 11, 2014

Dr. Hayley Henderson
Executive Editor, BMC Urology

Dear Dr. Henderson,
Thank you very much for reviewing our original manuscript entitled “Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells,” which we submitted for publication in BMC Urology (MS 7405179971246999). We have revised the manuscript according to the Editorial Requests.

Thanking you for consideration and looking forward to your favorable response,

Akinori Sato, M.D., Ph.D.
Department of Urology
National Defense Medical College
3-2 Namiki, Tokorozawa, Saitama 359-8513
Japan
Tel: +81-4-2995-1676
Fax: +81-4-2996-5210
E-mail: zenpaku@ndmc.ac.jp
Response to Editorial Requests

1. ARRIVE guidelines
In accordance with BioMed Central editorial policies (http://www.biomedcentral.com/about/editorialpolicies#StandardsofReporting), could you please ensure your manuscript reporting adheres to the ARRIVE guidelines (http://www.nc3rs.org.uk/page.asp?id=1357) for the reporting of animal experiments. This is so your methodology can be fully evaluated and utilised. Can you please include a completed ARRIVE checklist as an additional file when submitting your revised manuscript.

Response
We have added some descriptions about animal housing and husbandry in the Methods section (Lines 113-115). We also ensured that we reported the results of our animal experiment in compliance with the ARRIVE guidelines. Please find an attached completed ARRIVE checklist. In the previous revised manuscript, we had added the description about the ARRIVE guidelines, but we removed this description in this version because the guideline is not for our protocol (but for our report).

2. Ethical approval
Thank you for including this statement within the Methods. We would ask, however, that you include the full name of the ethics committee that approved your study in this statement.

Response
We added the full name of our committee in the Methods section (Lines 111-112).